EPSTEIN-BARR VIRUS AND NASOPHARYNGEAL CARCINOMA: VIRAL MARKERS FOR DIAGNOSTICS AND ASSESSMENT OF CLINICAL STATUS OF PATIENTS

Cover Page


Cite item

Full Text

Abstract

The etiological role of the Epstein-Barr virus (EBV) in the development of an undifferentiated histological variant of nasopharyngeal carcinoma (uNPC) found for the first time in regions with a high incidence of this pathology, the Southern provinces of China and the countries of Southeast Asia, and later in the rest of the world, has served as a basis for the widespread use of EBV serological markers for the diagnosis of this form of tumor. In recent years, the use of a test based on the quantitative determination of the EBV DNA concentration in the blood plasma of uNPC patients for early detection and monitoring of the disease has become widespread in endemic regions. In non-endemic regions, such studies virtually have not been carried out, and moreover, the comparative evaluation of the significance of two viral markers, serological and EBV DNA load in the bloodstream of uNPC patients, for diagnostics and evaluation of the therapeutic effect was not investigated. The aim of this study was to compare the clinical value of two serological markers and plasma EBV DNA load in uNPC patients from non-endemic region (Russia). The obtained results indicate that IgA antibodies to the viral capsid antigen (IgA/VCA) and plasma EBV DNA concentration can be successfully used for the diagnosis of uNPC, while IgG/VCA antibodies have no practical significance as an uNPC marker. In addition, it was found that plasma EBV DNA load is more sensitive marker of uNPC than IgA/VCA titers because DNA copy numbers reflect more accurately the effect of the therapy and the clinical state of patients at the stages of remission or relapse. It was shown for the first time that in the non-endemic region the simultaneous evaluation of IgA/VCA antibody levels and the plasma EBV DNA loads are the most effective markers for the diagnostics of uNPC. However, we believe, that it is more practical to use IgA/VCA antibody levels for uNPC screening, and plasma EBV DNA copies - for monitoring of the disease.

About the authors

V. N. Kondratova

N.N. Blokhin National Medical Cancer Research Center

Author for correspondence.
Email: noemail@neicon.ru
Russian Federation

M. V. Lomaya

N.N. Blokhin National Medical Cancer Research Center

Email: noemail@neicon.ru
Russian Federation

A. V. Ignatova

N.N. Blokhin National Medical Cancer Research Center

Email: noemail@neicon.ru
Russian Federation

T. E. Dushenkina

N.N. Blokhin National Medical Cancer Research Center

Email: noemail@neicon.ru
Russian Federation

K. V. Smirnova

N.N. Blokhin National Medical Cancer Research Center

Email: noemail@neicon.ru
Russian Federation

A. M. Mudunov

N.N. Blokhin National Medical Cancer Research Center

Email: noemail@neicon.ru
Russian Federation

A. V. Lichtenstein

N.N. Blokhin National Medical Cancer Research Center

Email: noemail@neicon.ru
Russian Federation

V. E. Gurtsevitch

N.N. Blokhin National Medical Cancer Research Center

Email: gurtsevitch-vlad-88@yandex.ru
Russian Federation

N. B. Senyuta

N.N. Blokhin National Medical Cancer Research Center

Email: noemail@neicon.ru
Russian Federation

References

  1. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer. 2004; 4(10): 757-68.
  2. Gu A.D., Zeng M.S., Qian C.N. The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation. Int. J. Mol. Sci. 2012; 13(10): 13737-47.
  3. Chang C.M., Yu K.J., Mbulaiteye S.M., Hildesheim A., Bhatia K. The extent of genetic diversity of Epstein-Barr virus and its geographic and disease patterns: a need for reappraisal. Virus Res. 2009; 143(2): 209-21.
  4. Yu M.C., Yuan J.M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 2002; 12(6): 421-9.
  5. Licitra L., Bernier J., Cvitkovic E., Grandi C., Spinazzé S., Bruzzi P., et al. Cancer of the nasopharynx. Crit. Rev. Oncol. Hematol. 2003; 45(2): 199-213.
  6. Давыдова М.И., Аксель Е.М., ред. Статистика злокачественных новообразований в России и странах СНГ в 2013 году. М.; 2015
  7. Barnes L., Eweson J.W., Reichart P., Sidransky D. Pathology and Genetics Head and Neck Tumours. Lyon: IARC Press; 2005.
  8. Brennan B. Nasopharyngeal carcinoma. Orphanet. J. Rare Dis. 2006; 1: 23.
  9. Luo S., Zhao L., Wang J., Xu M., Li J., Zhou B., et al. Clinical outcomes for early-stage nasopharyngeal carcinoma with predominantly WHO II histology treated by intensity-modulated radiation therapy with or without chemotherapy in nonendemic region of China. Head Neck. 2014; 36(6): 841-7.
  10. Cho W.C. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol. Cancer. 2007; 6: 1.
  11. Hubert A., De-Thé G. Dietary behavior, way of life, and nasopharyngeal cancer. Bull. Cancer. 1982; 69(5): 476-82.
  12. Li J., Qian C.N., Zeng Y.X. Regulatory T cells and EBV associated malignancies. Int. Immunopharmacol. 2009; 9(5): 590-2.
  13. Li X., Fasano R., Wang E., Yao K.T., Marincola F.M. HLA associations with nasopharyngeal carcinoma. Curr. Mol. Med. 2009; 9(6): 751-65.
  14. Tsao S.W., Tsang C.M., To K.F., Lo K.W. The role of Epstein-Barr virus in epithelial malignancies. J. Pathol. 2015; 235(2): 323-33.
  15. Yeung W.M., Zong Y.S., Chiu C.T., Chan K.H., Sham J.S., Choy D.T., et al. Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ. Int. J. Cancer. 1993; 53(5): 746-50.
  16. Gurtsevitch V., Ruiz R., Stepina V., Plachov I., Le Riverend E., Glazkova T., et al. Epstein-Barr viral serology in nasopharyngeal carcinoma patients in the USSR and Cuba, and its value for differential diagnosis of the disease. Int. J. Cancer. 1986; 37(3): 375-81.
  17. Pearson G.R. Epstein-Barr virus and nasopharyngeal carcinoma. J. Cell. Biochem. Suppl. 1993; 17F: 150-4.
  18. Ho H.C., Ng M.H., Kwan H.C. Factors affecting serum IgA antibody to Epstein-Barr viral capsid antigens in nasopharyngeal carcinoma. Br. J. Cancer. 1978; 37(3): 356-62.
  19. Song C., Yang S. A meta-analysis on the EBV DNA and VCA-IgA in diagnosis of Nasopharyngeal Carcinoma. Pak. J. Med. Sci. 2013; 29(3): 885-90.
  20. Lo Y.M., Chan L.Y., Chan A.T., Leung S.F., Lo K.W., Zhang J., et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumour recurrence in nasopharyngeal carcinoma. Cancer Res. 1999; 59(21): 5452-5.
  21. Hou X., Zhao C., Guo Y., Han F., Lu L.X., Wu S.X., et al. Different Clinical Significance of Pre- and Post-treatment Plasma Epstein-Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy. Clin. Oncol. (R. Coll. Radiol.). 2011; 23(2): 128-33.
  22. Wang W.Y., Twu C.W., Chen H.H., Jan J.S., Jiang R.S., Chao J.Y., et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin. Cancer Res. 2010; 16(3): 1016-24.
  23. Chan K.C., Chan A.T., Leung S.F., Pang J.C., Wang A.Y., Tong J.H., et al. Investigation into the origin and tumoural mass correlation of plasma Epstein-Barr virus DNA in nasopharyngeal carcinoma. Clin. Chem. 2005; 51(11): 2192-5.
  24. Fan H., Nicholls J., Chua D., Chan K.H., Sham J., Lee S., et al. Laboratory markers of tumour burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int. J. Cancer. 2004; 112(6): 1036-41.
  25. Lo Y.M., Leung S.F., Chan L.Y., Chan A.T., Lo K.W., Johnson P.J., et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer. Res. 2000; 60(9): 2351-5.
  26. Cao S.M., Liu Z., Jia W.H., Huang Q.H., Liu Q., Guo X., et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS One. 2011; 6(4): e19100.
  27. Chien Y.C., Chen J.Y., Liu M.Y., Yang H.I., Hsu M.M., Chen C.J., et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N. Engl. J. Med. 2001; 345(26): 1877-82.
  28. Kondo S., Horikawa T., Takeshita H., Kanegane C., Kasahara Y., Sheen T.S., et al. Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients. Cancer Sci. 2004; 95(6): 508-13.
  29. Leung S.F., Tam J.S., Chan A.T., Zee B., Chan L.Y., Huang D.P., et al. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin. Chem. 2004; 50(2): 339-45.
  30. Shao J.Y., Zhang Y., Li Y.H., Gao H.Y., Feng H.X., Wu Q.L., et al. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumour tissue in nasopharyngeal carcinoma. Anticancer Res. 2004; 24(6): 4059-66.
  31. Twu C.W., Wang W.Y., Liang W.M., Jan J.S., Jiang R.S., Chao J., et al. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2007; 67(1): 130-7.
  32. Zhao F.P., Liu X., Zhong Z.M., Lu J., Yu B.L., Zeng F.Y., et al. Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma. BBA Clin. 2014; 2: 88-93.
  33. Kondratova V.N., Botezatu I.V., Shelepov V.P., Lichtenstein A.V. Tube gel isotachophoresis: a method for quantitative isolation of nucleic acids from diluted solutions. Anal. Biochem. 2011; 408(2): 304-8.
  34. Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int. J. Cancer. 1976; 17(1): 1-7.
  35. Lawrence J.B., Villnave C.A., Singer R.H. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell. 1988; 52(1): 51-61.
  36. Chi K.R. The tumour trail left in blood. Nature. 2016; 532(7598): 269-71.
  37. Lichtenstein A.V., Melkonyan H.S., Tomei L.D., Umansky S.R. Circulating nucleic acids and apoptosis. Ann. N.Y. Acad. Sci. 2001; 945: 239-49.
  38. Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer. 2002; 2(3): 210-9.
  39. Skvortsova T.E., Rykova E.Y., Tamkovich S.N., Bryzgunova O.E., Starikov A.V., Kuznetsova N.P., et al. Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br. J. Cancer. 2006; 94(10): 1492-15.
  40. Gu A.D., Zeng M.S., Qian C.N. The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation. Int. J. Mol. Sci. 2012; 13(10): 13737-47.
  41. Peng H., Chen L., Zhang Y., Guo R., Li W.F., Mao Y.P., et al. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status. Oncotarget. 2016; 7(17): 24208-16.
  42. Zhao F.P., Liu X., Chen X.M., Lu J., Yu B.L., Tian W.D., et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma. Oncol. Lett. 2015; 10(5): 2888-94.
  43. Chen W.H., Tang L.Q., Zhang L., Chen Q.Y., Guo S.S., Liu L.T., et al. Combining plasma Epstein-Barr virus DNA and nodal maximal standard uptake values of 18F-fluoro-2-deoxy-D-glucose positron emission tomography improved prognostic stratification to predict distant metastasis for locoregionally advanced nasopharyngeal carcinoma. Oncotarget. 2015; 6(35): 38296-307.
  44. Chen W.H., Tang L.Q., Guo S.S., Chen Q.Y., Zhang L., Liu L.T., et al. Prognostic Value of Plasma Epstein-Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated with Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era. Medicine (Baltimore). 2016; 95(5): e2642.
  45. Zhang Y., Li W.F., Mao Y.P., Guo R., Tang L.L., Peng H., et al. Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma. Oncotarget. 2016; 7(8): 9576-85.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Kondratova V.N., Lomaya M.V., Ignatova A.V., Dushenkina T.E., Smirnova K.V., Mudunov A.M., Lichtenstein A.V., Gurtsevitch V.E., Senyuta N.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies